WARNING: The content of this website is for informational purposes only and not to be considered as medical advice. E-cigarettes are not approved by the FDA as a quit smoking aid. The products we review on this website, as well as the information provided, are intended for use by responsible adults over the age of 18 (or the legal tobacco possession age in your area).
Parkinson’s disease. Some early research shows that taking cannabidiol daily for 4 weeks improves psychotic symptoms in people with Parkinson’s disease and psychosis. But taking a specific cannabis extract (Cannador) that contains THC and cannabidiol does not appear to improve involuntary muscle movements caused by the anti-Parkinson’s drug levodopa in people with Parkinson’s disease.
Developed for the pharmacy sector, Canabidol™ products meet the exacting standards required by pharmacists for the retail sale of CBD. One of the longest standing brands in the UK, Canabidol™ has spearheaded the industry with it our dedication to excellence, passion for compliance and commitment to getting things right. The result has seen Canabidol™ products become the market leading brand in the pharmacy sector, with thousands of customers preferring Canabidol™. Which is now the only brand of choice in the UK, it’s the reason our thousands of registered official resellers now stock our products in high streets and major retail outlets across the country.
Until 2017, products containing cannabidiol marketed for medical purposes were classed as medicines by the UK regulatory body, the Medicines and Healthcare products Regulatory Agency (MHRA) and could not be marketed without regulatory approval for the medical claims. As of 2018, cannabis oil is legal to possess, buy, and sell in the UK, providing the product does not contain more than 0.3% THC and is not advertised as providing a medicinal benefit.
^ Jump up to: a b c Boggs, Douglas L; Nguyen, Jacques D; Morgenson, Daralyn; Taffe, Michael A; Ranganathan, Mohini (September 6, 2017). "Clinical and preclinical evidence for functional interactions of cannabidiol and Δ9-tetrahydrocannabinol". Neuropsychopharmacology. 43 (1): 142–154. doi:10.1038/npp.2017.209. ISSN 0893-133X. PMC 5719112. PMID 28875990.